Researchers presented a technique called rapid in vitro inhibition assay (RIVIA), whereby potential SARS-CoV-2 antibody and nanobody candidates can be rapidly screened.
Researchers engineered a mutant ACE2 decoy that effectively protected human lung epithelia from SARS-CoV-2 infection by competitively binding to its spike protein.